View Item 

Show simple item record

Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria
dc.contributor.authorSwiecicki, Paul L.
dc.contributor.authorBellile, Emily L.
dc.contributor.authorBrummel, Collin V.
dc.contributor.authorBrenner, J. Chad
dc.contributor.authorWorden, Francis P.
dc.date.accessioned2021-02-04T21:51:34Z
dc.date.available2022-02-04 16:51:33en
dc.date.available2021-02-04T21:51:34Z
dc.date.issued2021-01-15
dc.identifier.citationSwiecicki, Paul L.; Bellile, Emily L.; Brummel, Collin V.; Brenner, J. Chad; Worden, Francis P. (2021). "Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria." Cancer 127(2): 219-228.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/166220
dc.publisherWiley Periodicals, Inc.
dc.subject.otheraxitinib
dc.subject.otherhead and neck cancer
dc.subject.otherPI3K
dc.subject.othervascular endothelial growth factor receptor inhibitor
dc.subject.otherChoi criteria
dc.titleEfficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166220/1/cncr33226_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166220/2/cncr33226.pdf
dc.identifier.doi10.1002/cncr.33226
dc.identifier.doihttps://dx.doi.org/10.7302/143
dc.identifier.sourceCancer
dc.identifier.citedreferencede Almeida PE, Mak J, Hernandez G, et al. Anti‐VEGF treatment enhances CD8(+) T‐cell antitumor activity by amplifying hypoxia. Cancer Immunol Res. 2020; 8: 806 ‐ 818.
dc.identifier.citedreferenceCancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517: 576 ‐ 582.
dc.identifier.citedreferenceStrauss L, Volland D, Kunkel M, Reichert TE. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. Med Sci Monit. 2005; 11: BR280 ‐ BR292.
dc.identifier.citedreferenceHasina R, Whipple ME, Martin LE, Kuo WP, Ohno‐Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008; 88: 342 ‐ 353.
dc.identifier.citedreferenceSmith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000; 18: 2046 ‐ 2052.
dc.identifier.citedreferenceKyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta‐analysis. Clin Cancer Res. 2005; 11: 1434 ‐ 1440.
dc.identifier.citedreferenceOngkeko WM, Altuna X, Weisman RA, Wang‐Rodriguez J. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol. 2005; 124: 71 ‐ 76.
dc.identifier.citedreferenceBran B, Bran G, Hormann K, Riedel F. The platelet‐derived growth factor receptor as a target for vascular endothelial growth factor–mediated anti‐angiogenetic therapy in head and neck cancer. Int J Oncol. 2009; 34: 255 ‐ 261.
dc.identifier.citedreferenceSwiecicki PL, Zhao L, Belile E, et al. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Invest New Drugs. 2015; 33: 1248 ‐ 1256.
dc.identifier.citedreferenceChoi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753 ‐ 1759.
dc.identifier.citedreferenceHerbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5578 ‐ 5587.
dc.identifier.citedreferenceMotzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second‐line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14: 552 ‐ 562.
dc.identifier.citedreferenceHutson TE, Lesovoy V, Al‐Shukri S, et al. Axitinib versus sorafenib as first‐line therapy in patients with metastatic renal‐cell carcinoma: a randomised open‐label phase 3 trial. Lancet Oncol. 2013; 14: 1287 ‐ 1294.
dc.identifier.citedreferenceWolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune‐related response criteria. Clin Cancer Res. 2009; 15: 7412 ‐ 7420.
dc.identifier.citedreferenceVermorken JB, Trigo J, Hitt R, et al. Open‐label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum‐based therapy. J Clin Oncol. 2007; 25: 2171 ‐ 2177.
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F, et al. Platinum‐based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116 ‐ 1127.
dc.identifier.citedreferenceTerme M, Pernot S, Marcheteau E, et al. VEGFA‐VEGFR pathway blockade inhibits tumor‐induced regulatory T‐cell proliferation in colorectal cancer. Cancer Res. 2013; 73: 539 ‐ 549.
dc.identifier.citedreferenceDoedens AL, Phan AT, Stradner MH, et al. Hypoxia‐inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol. 2013; 14: 1173 ‐ 1182.
dc.identifier.citedreferenceSeiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE‐012): an open‐label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17: 956 ‐ 965.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856 ‐ 1867.
dc.identifier.citedreferenceTaylor MH, Rasco DW, Brose MS, et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck [abstract 6016]. J Clin Oncol. 2018; 36: 6016.
dc.identifier.citedreferenceKarar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011; 4: 51.
dc.identifier.citedreferenceManyam BV, Garsa AA, Chin RI, et al. A multi‐institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017; 123: 2054 ‐ 2060.
dc.identifier.citedreferenceVenables ZC, Autier P, Nijsten T, et al. Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England. JAMA Dermatol. 2019; 155: 298 ‐ 306.
dc.identifier.citedreferenceChaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294 ‐ 4301.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7 ‐ 30.
dc.identifier.citedreferenceMandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016; 1: e89829.
dc.identifier.citedreferenceBurtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE‐048): a randomised, open‐label, phase 3 study. Lancet. 2019; 394: 1915 ‐ 1928.
dc.working.doi10.7302/143en
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33226_am.pdf
Size:
446.0KB
Format:
PDF
View/Open
Name:
cncr33226.pdf
Size:
238.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.